Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$788.76 USD

788.76
1,497,572

+12.38 (1.60%)

Updated Nov 7, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Mark Vickery headshot

Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses

Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.

Eli Lilly (LLY) Tops Q4 Earnings and Revenue Estimates

Lilly (LLY) delivered earnings and revenue surprises of 0.81% and 5.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Take a Powder; PLTR, NXPI Beat in Q4

Market indices were reluctant to drag a stock market higher amid all-time high ranges on the Dow and S&P 500.

John Blank headshot

Tech Earnings Leadership: Global Week Ahead

Mainland China's "Year of the Dragon" starts on Friday. Yet the world's 2nd largest economy is anything but roaring right now. Meanwhile, tech earnings lead the way.

Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More

Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis

Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.

The Zacks Analyst Blog Highlights Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas

Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Eli Lilly, Danaher & Citigroup

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).

Kinjel Shah headshot

4 Large Drug Stocks Trying to Survive the Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Lilly (LLY) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know

Eli Lilly (LLY) concluded the recent trading session at $645, signifying a +0.9% move from its prior day's close.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Eli Lilly (LLY) settling at $629.68, representing a -0.19% change from its previous close.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

The Zacks Analyst Blog Highlights Eli Lilly, Linde, NextEra Energy, Honda Motor, Arthur J. Gallagher and Block

Eli Lilly, Linde, NextEra Energy, Honda Motor, Arthur J. Gallagher and Block are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Eli Lilly, Linde & NextEra Energy

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and NextEra Energy, Inc. (NEE).

Why Eli Lilly (LLY) Dipped More Than Broader Market Today

Eli Lilly (LLY) reachead $628.91 at the closing of the latest trading day, reflecting a -0.89% change compared to its last close.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Ethan Feller headshot

Bull of the Day: Regeneron Pharmaceuticals (REGN)

The Biotechnology company enjoys a litany of bullish catalysts on the horizon